MINOCYCLINE Injection
Infections caused by susceptible pathogens including resistant Acinetobacter
Key Facts
About Melinta Therapeutics
Melinta Therapeutics is a commercial-stage antibiotic company confronting the global public health threat of antimicrobial resistance (AMR). Founded in 2000, the company has navigated significant financial challenges, including a Chapter 11 restructuring in 2019, to maintain a portfolio of vital anti-infective agents. Its strategy centers on commercializing its approved products—BAXDELA (delafloxacin), KIMYRSA (oritavancin), MINOCYCLINE Injection, and VABOMERE (meropenem and vaborbactam)—while advancing its pipeline. The company operates in a high-need but commercially difficult market, reliant on strategic partnerships and public health initiatives for sustainable success.
View full company profile